N-Tense *HEF

Quantity: 120 Caps (700mg per cap.)
Price: 29.90€

Add to cart

Customer reviews (0)

N-Tense combines the rainforest's most potent and effective medicinal plants into one synergistic formula. N- Tense contains 50% of graviola combined with 7 other plants that have similar properties and actions as graviola. Most find this unique blend of rainforest plants to have synergistic actions and provide better results than graviola alone. Therefore, N- Tense is a great nutritional supplement to adjuvate anti-cancerous, anti-bacterial, anti-tumorous, immunostimulant and/or anti-viral treatments.

What's the meaning of "HEF"? To find out, click here.

Why should I purchase this N-Tense? To learn more, click here.

Ingredients: A proprietary blend of graviola, mullaca, guacatonga, espinheira santa, bitter melon, vassourinha, mutamba, and cat’s claw.

Suggested Use: As nutritional supplement, take 3- 4 capsules three times a day.

Contraindications:

Not to be used during pregnancy or while breast-feeding.
Some studies have documented estrogen-like actions of several ingredients contained in this formula. Individuals with estrogen-positive cancers shouldn't take this formula.
Some studies have demonstrated hypotensive, vasodilator, and cardiodepressant properties of several ingredients in this formula. Individuals with low blood pressure should monitor their blood pressure for this possible effect.

Drug Interactions: N-Tense may enhance or increase the effect of high blood pressure drugs.

Other Practitioner Observations:

Several ingredients in this formula have demonstrated significant in vitro antimicrobial properties. Supplementing the diet with probiotics (like acidophilus found in live-cultured yogurt) is advisable when this product is used for longer than 30 days.
Taking CoQ10 and other supplements which increase cellular ATP might reduce the effects of N-Tense.

Also Suggested:

Graviola, 100 capsules of 600 mg each of graviola (Annona muricata)
Graviola Max, a proprietary blend of two species of graviola (Annona muricata&Annona montana)

References

Graviola (Annona muricata)
Kojima, N. “Systematic synthesis of antitumor Annonaceous acetogenins” Yakugaku Zasshi. 2004; 124(10): 673-81
Tormo, J. R., et al. “In vitro antitumor structure-activity relationships of threo/trans/threo mono-tetrahydro-furanic acetogenins: Correlations with their inhibition of mitochondrial complex I.” Oncol. Res. 2003; 14(3): 147-54.
Yuan, S. S., et al. “Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase-3-related pathway.” Life Sci. 2003 May: 72(25): 2853-61.
Liaw, C. C., et al. “New cytotoxic monotetrahydrofuran Annonaceous acetogenins from Annona muricata.” J. Nat. Prod. 2002; 65(4): 470-75
Gonzalez-Coloma, A., et al. “Selective action of acetogenin mitochondrial complex I inhibitors.” Z. Naturforsch. 2002; 57(11-12): 1028-34.
Chang, F. R., et al. “Novel cytotoxic Annonaceous acetogenins from Annona muricata.” J. Nat. Prod. 2001; 64(7): 925-31.
Jaramillo, M. C., et al. “Cytotoxicity and antileishmanial activity of Annona muricata pericarp.” Fitoterapia. 2000; 71 (2): 183-6.
Betancur-Galvis, L., et al. “Antitumor and antiviral activity of Colombian medicinal plant extracts.” Mem. Inst. Oswaldo Cruz. 1999; 94(4): 531-35.
Kim, G. S., et al. “Muricoreacin and murihexocin C, mono-tetrahydrofuran acetogenins, from the leaves of Annona muricata.” Phytochemistry. 1998; 49(2): 565-71.
Kim, G. S., et al. “Two new mono-tetrahydrofuran ring acetogenins, annomuricin E and muricapentocin, from the leaves of Annona muricata.” J. Nat. Prod. 1998; 61(4): 432-36.
Nicolas, H., et al. “Structure-activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells.” J. Med. Chem. 1997; 40(13): 2102-6.
Zeng, L., et al. “Five new monotetrahydrofuran ring acetogenins from the leaves of Annona muricata.” J. Nat. Prod. 1996; 59(11): 1035-42.
Wu, F. E., et al. “Two new cytotoxic monotetrahydrofuran Annonaceous acetogenins, annomuricins A and B, from the leaves of Annona muricata.” J. Nat. Prod. 1995; 58(6): 830-36.
Oberlies, N. H., et al. “Tumor cell growth inhibition by several Annonaceous acetogenins in an in vitro disk diffusion assay.” Cancer Lett. 1995; 96(1): 55-62.
Wu, F. E., et al. “Additional bioactive acetogenins, annomutacin and (2,4-trans and cis)-10R-annonacin-A-ones, from the leaves of Annona muricata.” J. Nat. Prod. 1995; 58(9): 1430-37.
Wu, F. E., et al. “New bioactive monotetrahydrofuran Annonaceous acetogenins, annomuricin C and muricatocin C, from the leaves of Annona muricata.” J. Nat. Prod. 1995; 58(6): 909-5.
Wu, F. E., et al. “Muricatocins A and B, two new bioactive monotetrahydrofuran Annonaceous acetogenins from the leaves of Annona muricata.” J. Nat. Prod. 1995; 58(6): 902-8.
Sundarrao, K., et al. “Preliminary screening of antibacterial and antitumor activities of Papua New Guinean native medicinal plants.” Int. J. Pharmacog. 1993; 31(1): 3-6.

Mullaca (Physalis angulata)
Ausseil, F., et al. "High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources." J. Biomol. Screen. 2006 Dec 14;
Kuo, P. C., et al. "Physanolide A, a novel skeleton steroid, and other cytotoxic principles from Physalis angulata." Org. Lett. 2006 Jul; 8(14): 2953-6.
Ichikawa, H., et al. "Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression." Mol. Cancer Ther. 2006; 5(6): 1434-45.
Magalhaes, H. I., et al. "In-vitro and in-vivo antitumour activity of physalins B and D from Physalis angulata." J. Pharm. Pharmacol. 2006; 58(2): 235-41.
Jacobo-Herrera, N. J., et al. "Physalins from Witheringia solanacea as modulators of the NF-kappaB cascade." J. Nat. Prod. 2006; 69(3): 328-31.
Magalhaes, H. I., et al. "In-vitro and in-vivo antitumour activity of physalins B and D from Physalis angulata." J. Pharm. Pharmacol. 2006 Feb; 58(2): 235-41.
Hsieh, W. T., et al. “Physalis angulata induced G2/M phase arrest in human breast cancer cells.” Food Chem Toxicol. 2006; 44(7): 974-83.
Lee, C. C., et al. "Cytotoxicity of plants from Malaysia and Thailand used traditionally to treat cancer." J. Ethnopharmacol. 2005 Sep; 100(3): 237-43.
Wu, S. J., et al. “Antihepatoma activity of Physalis angulata and P. peruviana extracts and their effects on apoptosis in human Hep G2 cells.” Life Sci. 2004 Mar; 74(16): 2061-73.
Leyon, P. V., et al. "Effect of Withania somnifera on B16F-10 melanoma induced metastasis in mice." Phytother. Res. 2004; 18(2): 118-22.
Kawai, M., et al. “Cytotoxic activity of physalins and related compounds against HeLa cells.” Pharmazie 2002; 57(5): 348–50.
Ismail, N., et al. “A novel cytotoxic flavonoid glycoside from Physalis angulata.” Fitoterapia. 2001 Aug. 72(6):676–79.
Lee, Y. C., et al. “Integrity of intermediate filaments is associated with the development of acquired thermotolerance in 9L rat brain tumor cells.” J. Cell. Biochem. 1995; 57(1): 150–62.
Perng, M. D., et al. “Induction of aggregation and augmentation of protein kinase-mediated phosphorylation of purified vimentin intermediate filaments by withangulatin A.” Mol. Pharmacol. 1994; 46(4): 612–17.
Chiang, H., et al. “Antitumor agent, physalin F from Physalis angulata L.” Anticancer Res. 1992; 12(3): 837–43.
Chiang, H., et al. “Inhibitory effects of physalin B and physalin F on various human leukemia cells in vitro.” Anticancer Res. 1992; 12(4): 1155–62.
Kusumoto, I., et al. “Inhibitory effect of Indonesian plant extracts on reverse transcriptase of an RNA tumour virus (I).” Phytother. Res. 1992; 6(5): 241–44.
Lee, W. C., et al. “Induction of heat-shock response and alterations of protein phosphorylation by a novel topoisomerase II inhibitor, withangulatin A, in 9L rat brain tumor cells.” Cell Physiol. 1991; 149(1): 66-67.
Chen, C. M., et al. “Withangulatin A, a new withanolide from Physalis angulata.” Heterocycles. 1990; 31(7):1371–75.
Basey, K., et al. “Phygrine, an alkaloid from Physalis species.” Phytochemistry. 1992; 31(12): 4173–76.
Juang, J. K., et al. “A new compound, withangulatin A, promotes type II DNA topoisomerasemediated DNA damage.” Biochem. Biophys. Res. Commun. 1989; 159(3): 1128–34.
Anon. “Biological assay of antitumor agents from natural products.” Abstr.: Seminar on the Development of Drugs from Medicinal Plants Organized by the Department of Medical Science Department at Thai Farmer Bank, Bangkok, Thailand 1982; 129.
Antoun, M. D., et al. “Potential antitumor agents. XVII. physalin B and 25,26-epidihydrophysalin C from Witheringia coccoloboides.” J. Nat. Prod. 1981; 44(5): 579–85.

Guacatonga (Casearia sylvestris)
Balunas, M. J., et al. "Relationships between inhibitory activity against a cancer cell line panel, profiles of plants collected, and compound classes isolated in an anticancer drug discovery project." Chem. Biodivers. 2006; 3(8): 897-915.
Shen, Y. C., et al. "Cytotoxic clerodane diterpenoids from Casearia membranacea." J. Nat. Prod. 2005; 68(11): 1665-8.
Maistro, E. L., et al. “Evaluation of the genotoxic potential of the Casearia sylvestris extract on HTC and V79 cells by the comet assay.” Toxicol. In Vitro. 2004 Jun; 18(3): 337-42.
Oberlies, N. H., et al. “Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris.” J. Nat. Prod. 2002; 65(2): 95–99.
Sai Prakash, C. V., et al. “Structure and stereochemistry of new cytotoxic clerodane diterpenoids from the bark of Casearia lucida from the Madagascar rainforest.” J. Nat. Prod. 2002; 65(2): 100-7.
Beutler, J. A. “Novel cytotoxic diterpenes from Casearia arborea.” J. Nat. Prod. 2000; 63(5): 657-61.
Almeida, A. “Antitumor and anti-inflammatory effects of extract from Casearia sylvestris: comparative study with Piroxicam and Meloxicam.” Instituto de Ciencias Biomedicas, University of Sao Paulo (Dissertation, 4/02/99).
Itokawa, H., et al. “Antitumor substances from South American plants.” J. Pharmacobio. Dyn. 1992; 15(1): S-2-.
Morita, H., et al. “Structures and cytotoxic activity relationship of casearins, new clerodane diterpenes from Casearia sylvestris Sw.” Chem. Pharm. Bull. (Tokyo) 1991 Dec; 39(3): 693–97.
Itokawa, H., et al. “New antitumor principles, casearins A–F, for Casearia sylvestris Sw. (Flacourtiaceae).” Chem. Pharm. Bull. (Tokyo) 1990; 38(12): 3384–88.
Itokawa, H., et al. “Isolation of diterpenes as antitumor agents from plants.” Patent—Japan Kokai Tokyo Koho–01 1989; 149, 779: 6pp.
Itokawa, H., et al. “Antitumor principles from Casearia sylvestris Sw. (Flacourtiaceae), structure elucidation of new clerodane diterpenes by 2-D NMR spectroscopy.” Chem. Pharm. Bull. (Tokyo) 1988 March; 36(4): 1585–88.

Espinheira Santa (Maytenus ilicifolia)
Liu Z, et al. “Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry.” J. Mass. Spectrom. 2005; 40(3): 389-99.
Nakao, H., et al. “Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells.” Biol. Pharm. Bull. 2004; 27(8): 1236-40.
Cassady, J. M., et al. “Recent developments in the maytansinoid antitumor agents.” Chem. Pharm. Bull. 2004; 52(1): 1-26.
Ohsaki, A., et al. “Four new triterpenoids from Maytenus ilicifolia.” J. Nat. Prod. 2004; 67(3): 469-71.
Horn, R. C., et al. “Antimutagenic activity of extracts of natural substances in the Salmonella/microsome assay.” Mutagenesis. 2003 Mar; 18(2): 113-8.
Buffa Filho, W., et al. “Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography.” Phytochem. Anal. 2002 Mar-Apr; 13(2): 75-8.
Miura, N. et al. “Protective effects of triterpene compounds against the cytotoxicity of cadmium in HepG2 cells.” Mol. Pharm. 1999; 56(6); 1324–28.
Liu, C., et al. “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.” Proc. Natl. Acad. Sci. 1996 Aug; 93(16): 8618-23.
Shirota, O., et al. “Cytotoxic aromatic triterpenes from Maytenus ilicifolia and Maytenus chuchuhuasca.” J. Nat. Prod. 1994; 57(12): 1675–81.
Itokawa, H., et al. “Cangorins F–J, five additional oligo-nicotinated sesquiterpene polyesters from Maytenus ilicifolia." J. Nat. Prod. 1994; 57(4): 460–70.
Arisawa, M., et al. “Cell growth inhibition of KB cells by plant extracts.” Natural Med. 1994; 48(4): 338–347.
Itokawa, H., et al. “Oligo-nicotinated sesquiterpene polyesters from Maytenus ilicifolia." J. Nat. Prod. 1993; 56(9); 1479–1485.
Itokawa, H., et al. “Antitumor substances from South American plants.” Pharmacobio. Dyn. 1992; 15(1): S
Fox, B. W. “Medicinal plants in tropical medicine. 2. Natural products in cancer treatment from bench to the clinic.” Trans. R. Soc. Trop. Med. Hyg. 1991; 85(1): 22-5.
Ravry, M. J., et al. “Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial.” Am. J. Clin. Oncol. 1985 Apr; 8(2): 148-50.
Suffnes, M. J., et al. “Current status of the NCI plant and animal product program.” J. Nat. Prod. 1982; 45: 1–14.
Cabanillas, F., et al. “Phase I study of maytansine using a 3-day schedule.” Cancer Treatment Reports. 1976; (60): 1127–39.
Chabner, B. A., et al. “Initial clinical trials of mayansine, an antitumor plant alkaloid.” Cancer Treatment Reports. 1978; (62): 429–33.
O'Connell, M. J., et al. “Phase II trial of maytansine in patients with advanced colorectal carcinoma.” Cancer Treatment Reports. 1978 (62); 1237-38.
Wolpert-Defillipes, M. K., et al. “Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide.” Biochemical Pharmacology. 1975; 24: 751–54.
Melo, A. M., et al. “First observations on the topical use of primin, plumbagin and maytenin in patients with skin cancer.” Rev. Inst. Antibiot. 1974 Dec.
Monache, F. D., et al., “Maitenin: A new antitumoral substance from Maytenus sp.” Gazetta Chimica Italiana 1972; 102: 317–20.
de Santana, C. F., et al. “Primeiras observacoes sobre o emprego da maitenina em pacientes cancerosos.” Rev. Inst. Antibiot. 1971; 11: 37–49.
Hartwell, J. L. “Plants used against cancer: A survey.” Lloydia. 1968; 31: 114.

Bitter Melon (Momordica charantia)
Hwang, Y., et al. "Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival." Biochem. Biophys. Res. Commun. 2005 Nov; 337(3): 815-23.
Yasui, Y., et al. “Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells.” Prostaglandins Leukot. Essent. Fatty Acids. 2005 Aug; 73(2): 113-9.
Ike, K., et al. “Induction of interferon-gamma (IFN-gamma) and T helper 1 (Th1) immune response by bitter gourd extract.” J. Vet. Med. Sci. 2005; 67(5): 521-4.
Nagasawa, H., et al. “Effects of bitter melon (Momordica charantia) or ginger rhizome (Zingiber offifinale Rosc.) on spontaneous mammary tumorigenesis in SHN mice.” Am. J. Clin. Med. 2002; 30(2–3): 195–205.
Kim, J. H., et al. “Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells.” Anticancer Res. 2002 May-Jun; 22(3): 1885-9.
Tazzari, P. L., et al. “An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30 anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.” Haematologica. 1999; 84(11): 988-95.
Lee, D. K., et al. “Momordins inhibit both AP-1 function and cell proliferation.” Anticancer Res. 1998 Jan-Feb; 18(1A): 119-24.
Terenzi, A., et al. “Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumor activity against CD30 tumor cells in vitro and in SCID mice.” Br. J. Haematol. 1996; 92(4): 872–79.
Bolognesi, A., et al. “Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.” Int. J. Cancer. 1996 Nov; 68(3): 349-55.
Battelli, M. G., et al. “Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line.” Int. J. Cancer. 1996 Feb; 65(4): 485-90.
Lee-Huang, S., et al. “Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.” Gene. 1995; 161(2):151–56.
Cunnick, J. E., et al. “Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia).” Cell Immunol. 1990 Apr; 126(2): 278-89.
Zhu, Z. J., et al. “Studies on the active constituents of Momordica charantia l.” Yao. Hsueh. Hsueh. Pao. 1990; 25(12): 898–903.
Stirpe, F., et al. “Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.” Br. J. Cancer. 1988 Nov; 58(5): 558-61.
Takemoto, D. J., et al. “Purification and characterization of a cytostatic factor with anti-viral activity from the bitter melon. Part 2.” Prep Biochem. 1983; 13(5): 397-421.
Takemoto, D. J., et al. “The cytotoxic and cytostatic effects of the bitter melon (Momordica charantia) on human lymphocytes.” Toxicon. 1982; 20: 593–99.
Takemoto, D. J., et al. “Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts.” Enzyme. 1982; 27(3): 179–88.
Takemoto, D. J., et al. “Partial purification and characterization of a guanylate cyclase inhibitor with cytotoxic properties from the bitter melon (Momordica charantia).” Biochem. Biophys. Res. Commun. 1980; 94(1): 332–39.
Claflin, A. J., et al. “Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).” Proc. Natl. Acad. Sci. 1978; 75(2): 989–93.
Vesely, D. L., et al. “Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abbreviata).” Biochem. Biophys. Res. Commun. 1977; 77(4): 1294–99.

Vassourinha (Scoparia dulcis)
Kessler, J. H., et al. "Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types." Cancer Lett. 2006 Dec 12;
Mukherjee, R., et al. "Betulinic acid derivatives as anticancer agents: structure activity relationship." Anticancer Agents Med. Chem. 2006 May; 6(3): 271-9.
Phan, M. G., et al. "Chemical and biological evaluation on scopadulane-type diterpenoids from Scoparia dulcis of Vietnamese origin." Chem. Pharm. Bull. 2006 Apr; 54(4): 546-9.
Hayashi, K., et al. "The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy." J. Gene Med. 2006 Aug; 8(8): 1056-67.
Kasperczyk, H., et al. “Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy.” Oncogene. 2005 Oct; 24(46): 6945-56.
Fulda, S., et al. “Sensitization for anticancer drug-induced apoptosis by betulinic acid.” Neoplasia. 2005; 7(2): 162-70.
Garg, A. K., et al. “Chemosensitization and radiosensitization of tumors by plant polyphenols.” Antioxid. Redox. Signal. 2005; 7(11-12): 1630-47.
Wada, S., et al. "Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of Bischofia javanica." Chem. Biodivers. 2005 May; 2(5): 689-94.
Hayashi, K., et al. “Evaluation of scopadulciol-related molecules for their stimulatory effect on the cytotoxicity of acyclovir and ganciclovir against Herpes simplex virus type 1 thymidine kinase gene-transfected HeLa cells.” Chem. Pharm. Bull. 2004; 52(8):1015-7.
Ahsan, M., et al. “Cytotoxic diterpenes from Scoparia dulcis.” J. Nat. Prod. 2003; 66(7): 958-61.
Fulda, S., et al. “Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroecto-dermal tumors.” Med. Pediatr. Oncol. 2000; 35(6): 616–18.
Fulda, S., et al. “Betulinic acid: A new cytotoxic agent against malignant brain-tumor cells.” Int. J. Cancer 1999; 82(3): 435–41.
Noda, Y., et al. “Enhanced cytotoxicity of some triterpenes toward leukemia L1210 cells cultured in low pH media; possibility of a new mode of cell killing.” Chem. Pharm. Bull. 1997; 45(10): 1665–70.
Arisawa, M. “Cell growth inhibition of KB cells by plant extracts.” Natural Med. 1994; 48(4): 338–47.
Nishino, H. “Antitumor-promoting activity of scopadulcic acid B, isolated from the medicinal plant Scoparia dulcis L." Oncology. 1993; 50(2): 100–3.
Hayashi, T., et al. “Scoparic acid A, a beta-glucuronidase inhibitor from Scoparia dulcis.” J. Nat. Prod. 1992; 55(12): 1748
Hayashi, R. J., et al. “A cytotoxic flavone from Scoparia dulcis L.” Chem. Pharm. Bull. 1988; 36: 4849–51.

Mutamba (Guazuma ulmifolia)
Seigler, D. S. “Cyanogenic glycosides and menisdaurin from Guazuma ulmifolia, Ostrya virgininana, Tiquilia plicata and Tiquilia canescens.” Phytochemistry. 2005 Jul; 66(13): 1567-80.
Ito, H., et al. “Antitumor activity of compounds isolated from leaves of Eriobotrya japonica.” J. Agric. Food Chem. 2002; 50(8): 2400–3.
Kashiwada, Y., et al. “Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.” J. Nat. Prod. 1992; 55(8): 1033–43.
Nascimento, S. C., et al. “Antimicrobial and cytotoxic activities in plants from Pernambuco, Brazil.” Fitoterapia. 1990; 61(4): 353–55.

Cat’s Claw (Uncaria tomentosa)
Gonzales, G.F., et al. "Medicinal plants from Peru: a review of plants as potential agents against cancer." Anticancer Agents Med. Chem. 2006 Sep; 6(5): 429-44.
De Martino, L., et al. "Proapoptotic effect of Uncaria tomentosa extracts." J. Ethnopharmacol. 2006 Aug; 107(1): 91-4.
Bacher, N., et al. "Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells." Br. J. Haematol. 2006 Mar; 132(5): 615-22.
Riva, L., et al. “The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line." Anticancer Res. 2001; 21(4A): 2457–61.
Muhammad, I., et al. “Investigation of Una de Gato I. 7-Deoxyloganic acid and 15N NMR spectroscopic studies on pentacyclic oxindole alkaloids from Uncaria tomentosa." Phytochemistry. 2001; 57(5): 781–5.
Sheng Y, et al., “Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa.” Phytomedicine. 2000; 7(2): 137–43.
Sheng, Y., et al. “Induction of apoptosis and inhibition of proliferation in human tumor cells treated with extracts of Uncaria tomentosa." Anticancer Res. 1998; 18(5A): 3363–68.
Salazar, E. L., et al. “Depletion of specific binding sites for estrogen receptor by Uncaria tomentosa." Proc. West. Pharmacol. Soc. 1998; 41(1): 123–124.
Stuppner, H., et al. “A differential sensitivity of oxindole alkaloids to normal and leukemic cell lines.” Planta Med. (1993 suppl.); 59: A583.
Rizzi, R., et al. “Mutagenic and antimutagenic activities of Uncaria tomentosa and its extracts." J. Ethnopharmacol. 1993; 38: 63–77.
Peluso, G., et al. “Effetto antiproliferativo su cellule tumorali di estrattie metaboliti da Uncaria tomentosa. Studi in vitro sulla loro azione DNA polimerasi.” 11 Congreso Italo-Peruano de Etnomedicina Andina, Lima, Peru, October 27–30, 1993, 21–2.
Rizzi, R., et al. “Bacterial cytotoxicity, mutagenicity and antimutagenicity of Uncaria tomentosa and its extracts. Antimutagenic activity of Uncaria tomentosa in humans." Premiere Colloque Européan d'Ethnopharmacologie, Metz, France, March 22–24, 1990.

Following up, an article on Graviola proprieties by Health Science Institute and with kindly licence of Raintree Nutrition:

Billion-dollar drug company nearly squashes astounding research on natural cancer killer

Colon and breast cancer conquered with miracle tree from the Amazon found to be 10,000 times stronger than chemotherapy

Since our inception in 1996, Health Sciences Institute has scoured the world to find cutting-edge treatments few people have access to or have even heard about. And sometimes, what we uncover startles even the medical mavericks on our board.

Two months ago, we learned about an astounding cancer-fighting tree from the Amazon that has literally sent shock waves through the HSI network.
Today, the future of cancer treatment and the chances of survival look more promising than ever. There's a healing tree that grows deep within the Amazon rain forest in South America that could literally change how you, your doctor, and possibly the rest of the world think about curing cancer.

With extracts from this powerful tree, it may now be possible to…

conquer cancer safely and effectively with an all-natural therapy that doesn't cause extreme nausea, weight loss, and hair loss
protect your immune system and evade deadly infections
feel strong and healthy throughout the course of treatment
boost your energy and improve your outlook on life

Through a series of confidential communications involving a researcher from one of America's largest pharmaceutical companies, this ancient tree's anticancerous properties have recently come to light. Although not yet tested in human trials, the tree has been studied in more than 20 laboratory tests since the 1970s, where it's been shown that:

effectively target and kill malignant cells in 12 different types of cancer, including colon, breast, prostate, lung, and pancreatic cancer
be 10,000 times stronger in killing colon cancer cells than Adriamycin, a commonly used chemotherapeutic drug
selectively hunt down and kill cancer cells without harming healthy cells, unlike chemotherapy

So why isn't every health publication extolling the benefits of this treatment? Why hasn't it been made widely available throughout the natural-medicine community? And, if it's only half as promising as it appears to be, why isn't every oncologist at every major hospital insisting on using it on all his patients? Especially when you consider that since the early 1990s, extensive independent research-including research by one of today's leading drug companies and by the National Cancer Institute-confirms that the tree's chemical extracts attack and destroy cancer cells with lethal precision.

The answer to these difficult questions can only be explained by recounting a disturbing story we recently uncovered. More than anything else we've reported on this year, the story of this Amazon cancer treatment reinforces the need for groups like HSI and illustrates how easily our options for medical treatment are controlled by money and power.

News of this amazing tree was nearly lost forever

A confidential source, whose account we've been able to independently confirm, revealed that a billion-dollar drug company in the United States tried for nearly seven years to synthesize two of the tree's most powerful anticancerous chemicals. In the early 1990s, behind lock and key, this well-known drug giant began searching for a cure for cancer-while preciously guarding their opportunity to patent it and, therefore, profit from it.

Research focused on a legendary healing tree called Graviola. Parts of the tree-including the bark, leaves, roots, fruit, and fruit seeds-had been used for centuries by medicine men and native Indians in South America to treat heart disease, asthma, liver problems, and arthritis. Going on little documented scientific evidence, the company poured money and resources into testing Graviola's anticancerous properties-and they were shocked by the results. Graviola was a cancer-killing dynamo. But that's where the story of Graviola nearly ended.

The pharmaceutical company had a big problem. They'd spent years trying to isolate and create man-made duplicates of two of the tree's most powerful chemicals. But they'd hit a brick wall. They couldn't replicate the original. And they couldn't sell the tree extract itself profitably-because federal law mandates that natural substances can't be patented. That meant the company couldn't protect its profits on the project it had poured millions of dollars and nearly seven years of research into.

As the dream of big profits evaporated, testing on Graviola came to a screeching halt

After seven frustrating years and without the promise of lucrative sales, the company shelved the project and refused to publish its findings in an independent journal. But one responsible researcher struggled with the decision. While understanding the company's goal of profits, he couldn't accept the decision to hide this unique cancer killer from the world. Following his conscience and risking his career, he contacted Raintree Nutrition, a company dedicated to harvesting plants from the Amazon.
As a result, Raintree went into high gear and began to research related studies published on Graviola. They discovered that several other teams in the United States (in addition to that of the drug company) had been testing Graviola in vitro (in test tubes). The results supported the drug company's secret findings; Graviola had been shown to kill cancer cells.
Encouraged by these early laboratory tests, Raintree hired indigenous Indian tribes in Brazil to grow and harvest the tree. They spent a year on research and development and then began offering Graviola in the United States. They also developed a new supplement called N-Tense, which contains 50 percent Graviola as well as smaller amounts of seven other cancer-killing botanical extracts.

Health Sciences Institute came across Graviola and Raintree Nutrition a few months ago while researching Chanca Piedra, a natural kidney-stone therapy from the Amazon, that was featured in our September 2000 issue. In the course of our working together, Raintree pointed us toward Graviola. And needless to say, our panel of experts were intrigued by the possibility of this powerful natural cure for cancer.

Graviola hunts down and destroys prostate, lung, breast, colon, and pancreatic cancers… leaving healthy cells alone

Since November, we've been looking closely into the research to date on Graviola. It appears one of the first scientific references to it in the United States was by the National Cancer Institute (NCI). In 1976, the NCI included Graviola in a plant-screening program that showed its leaves and stems were effective in attacking and destroying malignant cells. But the results were part of an internal NCI report and were, for some reason, never released to the public.

Since 1976, there have been several promising cancer studies on Graviola. However, the tree's extracts have yet to be tested on cancer patients. No double-blind clinical trials exist, and clinical trials are typically the benchmark mainstream doctors and journals use to judge a treatment's value. Nevertheless, Graviola has been shown to kill cancer cells in vitro in at least 20 laboratory tests that our research has uncovered.

The most recent study, conducted at Catholic University of South Korea earlier this year, revealed that two chemicals extracted from Graviola seeds showed "selective cytotoxicity comparable with Adriamycin" for breast and colon cancer cells. The chemicals targeted and killed malignant breast and colon cells in a test tube-comparable to the commonly used chemotherapy drug Adriamycin.2
Another study, published in the Journal of Natural Products, showed that Graviola is not only comparable to Adriamycin-but dramatically outperforms it in laboratory tests. Results showed that one chemical found in Graviola selectively killed colon cancer cells at "10,000 times the potency of Adriamycin."

Other promising and ongoing research at Purdue University is supported by a grant from the National Cancer Institute. Purdue researchers recently found that leaves from the Graviola tree killed cancer cells "among six human-cell lines" and were especially effective against prostate and pancreatic cancer cells.

In a separate study, Purdue researchers showed that extracts from the Graviola leaves are extremely effective in isolating and killing lung cancer cells.

Perhaps the most significant result of the study cited above from the Catholic University of South Korea, and of each of the others we've found, is that Graviola was shown to selectively target the enemy-leaving all healthy, normal cells untouched. By comparison, chemotherapy indiscriminately seeks and destroys all actively reproducing cells-even normal hair and stomach cells. This is what causes such often-devastating side effects as hair loss and severe nausea. In this respect, Graviola looks to be a promising alternative or supplement to mainstream treatments.

Patient reports show Graviola and N-Tense help eliminate tumors

From a clinical standpoint, Graviola still has a long way to go. Its properties have only been studied in a test tube. That's why it has yet to become widely known and accepted. The unfortunate truth is that without the promise of huge revenues from a synthesized, patented drug, it's unlikely that any pharmaceutical company will invest the hundreds of thousands (even millions) of dollars it would take to conduct the double-blind, placebo-controlled studies on humans. This is the underlying challenge to substantiating most nutritional therapies. Fortunately, Graviola is a natural substance, so we don't have to wait around for the drug companies. And, thanks to one researcher with a conscience, Raintree Nutrition bravely took the initiative in making this promising cure available.
Only a relative handful of doctors and patients in the United States have been using Graviola and the Graviola-rich botanical supplement N-Tense to fight cancer. Still, according to Raintree Nutrition, the combined therapy has produced some incredible results.

One such case history involved an executive at a high-tech company in Texas. Daryl S. came across Raintree when exploring alternative treatments to cure his prostate cancer. A sonogram and biopsy confirmed that Daryl had more than 20 tumors in his prostate. One doctor recommended surgery. But Daryl thought a cure using this common conventional treatment would come at too great a cost. He didn't want to suffer from impotence and incontinence for the rest of his life.

Instead, he agreed to a far less invasive round of hormonal therapy (to shrink the size of his prostate) and began a rigorous supplement regimen that centered around the Graviola-rich supplement N-Tense.

Within two months, Daryl's PSA level had dropped from 4.1 to 0.00. A sonogram and several other gamma-ray tests later confirmed that all the malignant tumors inside his prostate had disappeared.

Seven years of silence broken

We are continuing to work with Raintree and others conducting ongoing research on Graviola. As more scientific and anecdotal evidence comes to light, you'll be among the first to hear about it. However, after seven years of silence and hidden research, we felt it irresponsible not to bring this to you now.

Grown and harvested by indigenous people in Brazil, Graviola is available in limited supply in the United States and distributed only through Raintree Nutrition. But now, you can be among a select few in the entire country to benefit from Graviola. We encourage you, as always, to consult with your doctor before beginning any new therapy, especially when treating cancer.

Despite the mounting collection of laboratory tests and anecdotal reports about this cancer-fighting dynamo, Graviola may always remain an underground therapy!

Graviola has yet to be clinically tested on animals or humans. And because Graviola is a natural product, it can't be patented. Without the promise of exclusive sales and high profitability, it will likely never again draw the attention of a major drug company or research lab. So we may never see a double-blind clinical study on the tree that's reported to help defeat cancer.

But there's no doubt about it-the early laboratory tests and anecdotal reports about Graviola are very exciting. And if you've been diagnosed with cancer, you and your doctor should look at all the available treatment options. Graviola may just provide the help you've been looking for that could make all the difference in beating cancer.

Graviola fights more than cancer…

While the research on Graviola has focused on its cancer-fighting effect, the plant has been used for centuries by medicine men in South America to treat an astonishing number of ailments, including:

hypertension
influenza
rashes
neuralgia
arthritis
rheumatism
diarrhea
nausea
dyspepsia
ulcers
ringworm
scurvy
malaria
dysentery
palpitations
nervousness
insomnia
fever
boils
muscle spasm

WARNINGS: The statements given in these pages have an informative aim and are drawned on international publications. The natural properties of the botanicals are only referred to their common uses among folk and herbal traditions. Our products are not intended to diagnose, cure, or prevent any disease as well. It's not meant to give any suggestion of diagnosis or disesase treatment. Please see a doctor when needed.